Autonomix Secures Broad U.S. Patent for Nerve Sensing and Targeted Therapy Platform
AMIX has more than doubled off its 52-week low of $2.44 on light trading volume (0.1× avg).
Summary
Autonomix Medical has been granted U.S. Patent No. 12,433,670, significantly expanding its intellectual property for precision neuromodulation. The patent covers systems that sense, map, and selectively target nerves associated with tumors and cancer pain, with potential applications across multiple solid tumor types and autonomic disorders. This follows a prior patent in May for transvascular monitoring, but the new claims broaden the platform's therapeutic scope. For a micro-cap company with a going concern warning and ongoing ATM dilution, a strengthened patent portfolio is a modest positive that reinforces the technology's potential, though commercialization remains distant. The company recently regained Nasdaq compliance and raised $2.6M via warrant inducement, but faces significant cash constraints.
At the time of this announcement, AMIX was trading at $6.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $2.44 to $32.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.